Pregabalin NDC 72205-079

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-079Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0079Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-079-30	72205007930	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (72205-079-30)Marketed from Apr 13, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pregabalin
Generic name (nonproprietary): pregabalin
Active ingredients: Pregabalin — 330 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Novadoz Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213226
Marketing start: Apr 13, 2021
Listing expires: Dec 31, 2027
DEA schedule: CV
Identifiers: Product ID 72205-079_19d54064-0d2c-447e-93a7-84d2b99c4bc9SPL ID 19d54064-0d2c-447e-93a7-84d2b99c4bc9SPL set ID f6aa5977-97c8-4a56-8e35-d9ab5cc24369RxCUI 1988974, 1988977, 1988980UNII 55JG375S6MUPC 0372205079304, 0372205078307, 0372205077300

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472205007930 followed by a unit qualifier and the quantity

Package 72205-0079-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 10, 2026.

Indications (excerpt from the label)

Pregabalin extended-release tablets are indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy Postherpetic neuralgia Efficacy of pregabalin extended-release tablets has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. Pregabalin extended-release tablets are indicated for the management of: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) Postherpetic neuralgia (PHN) ( 1 ) Efficacy of pregabalin extended-release tablets has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seiz…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213226

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213226
Product	Strength	Form · route	Labeler	Product NDC
Pregabalin	Pregabalin 82.5 mg/1	Tablet, Film coated, Extended releaseOral	Novadoz Pharmaceuticals LLC	72205-077
Pregabalin	Pregabalin 165 mg/1	Tablet, Film coated, Extended releaseOral	Novadoz Pharmaceuticals LLC	72205-078